INVIVYD, INC. Other Current Assets
INVIVYD, INC. (IVVD) had Other Current Assets of $2.37 million as of 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:OtherAssetsCurrent · last filed 2025-08-14
- 2025-06-30: Other Assets, Current $2.37M.
- 2024-12-31: Other Assets, Current $3.73M.
- 2021-12-31: Other Assets, Current $1.52M.
- 2021-09-30: Other Assets, Current $579.00K.
| Period end | Other Assets, Current | Other Assets, Current as first filed |
|---|---|---|
| 2025-06-30 | $2.37M 10-Q · filed 2025-08-14 | |
| 2024-12-31 | $3.73M 10-Q · filed 2025-08-14 | |
| 2021-12-31 | $1.52M 10-K · filed 2022-03-31 | |
| 2021-09-30 | $579.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $261.00K 10-Q · filed 2021-09-20 | |
| 2020-12-31 | $100.00K 10-K · filed 2022-03-31 | $63.00K 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |